[Intralesional therapy using recombinant interferon alpha 2 B in lesions of the uterine cervix caused by human papilloma virus].
A clinical study on 20 patients with uterine cervix Human Papilloma Virus (HPV) lesions treated with intralesional recombinant alpha 2b interferon (3 millions I.U.) three times a week for three weeks where possible, is presented. After one year from treatment, lesions were cured or stabilized in 18 Patients (90%); progression was observed in 2 patients (10%) for which reason traditional surgical therapy was performed.
Germano
A
A
Stellato
G
G
Lombardo
G
G
de Simone
A
A
Semenza
G
G
D000328:Adult; D000368:Aged; D002278:Carcinoma in Situ / Q000209:etiology / Q000628:therapy*; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D027383:Papillomaviridae; D011994:Recombinant Proteins; D014412:Tumor Virus Infections / Q000150:complications*; D002583:Uterine Cervical Neoplasms / Q000209:etiology / Q000628:therapy*
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Terapia intralesionale con interferone alfa 2 B ricombinante in lesioni della cervice uterina da human papilloma virus (HPV).